Objective:To exploring the uptake of fibroblast activation protein (FAP) inhibitor (FAPI) in pancreatic cancer through 68Ga-FAPI-04 PET/CT imaging, and provide a basis for the FAP-targeted imaging of pancreatic cancer. Methods:Pancreatic cancer-patient-derived tumor xenograft (PDX) mouse models ( n=8) were developed, then 68Ga-FAPI-04 and 18F-FDG microPET/CT imaging were performed (4 in each group). The differences of percentage activity of injection dose per gram of tissue (%ID/g) of 68Ga-FAPI-04 and 18F-FDG were analyzed by independent-sample t test. 68Ga-FAPI-04 and 18F-FDG PET/CT imaging were performed in 5 patients (4 males, 1 female, age: 46-74 (63.0±11.9) years) with pancreatic cancer, and the maximum standardized uptake value (SUV max) of 68Ga-FAPI-04 and 18F-FDG in primary pancreatic cancer and the SUV max ratio of liver metastases to liver tissue were compared by paired t test. Results:MicroPET/CT imaging showed that 68Ga-FAPI-04 was obviously uptaken at all time points in the tumor of PDX mice. The uptake of 68Ga-FAPI-04 in PDX mice 60 min after injection was significantly higher than that of 18F-FDG ((6.58±0.44) and (4.29±0.13) %ID/g; t=4.152, P=0.008 9). PET/CT showed that the SUV max of 68Ga-FAPI-04 in pancreatic cancer was significantly higher than that of 18F-FDG (16.82±3.08 and 5.14±2.20; t=6.893, P=0.000 1) and the SUV max ratio of liver metastases to liver tissue of 68Ga-FAPI-04 was also significantly higher than that of 18F-FDG (4.57±1.47 and 1.30±0.16; t=3.803, P=0.019 1). Conclusion:68Ga-FAPI-04 can be highly uptaken in pancreatic cancer, suggesting that FAP can be a potential target for PET/CT imaging of pancreatic cancer.

OBJECTIVE： To study the antimicrobial activity of ampelopsin combined with 8 kinds of antibiotic against Pseudomonas aeruginosa （PA） in vitro. METHODS： Chessboard trace dilution method was used to determine minimum inhibitory concentration （MIC） of ampelopsin combined with ceftriaxone， cefoperazone/sulbactam， piperacillin/tazobactam， cefoperazone， ciprofloxacin， amikacin， piperacillin and cefepime to PA strain ATCC27853 and 7 isolated strains PA135， PA216， PA276， PA281， PA291， PA314 and PA319. Fractional inhibitory concentration index （FICI） was used to evaluate its effects of drug combination. Clinically isolated strain PA319 were taken as target strain and then divided into normal control group， ampelopsin alone group， antibiotics alone group and ampelopsin+antibiotic combination group. Using MIC of ampelopsin and antibiotics during drug combination as active concentration， the number of colonies cultured for 0， 4， 8， 12 and 24 h was counted， and the time-sterilization curve was drawn. RESULTS： For above 8 kinds of strains， MIC of ampelopsin alone was 128-256 mg/L； FICI of ampelopsin combined with ceftriaxone， cefoperazone/sulbactam， piperacillin/tazobactam， cefoperazone， ciprofloxacin， amikacin， piperacillin and cefepime to 8， 8， 7， 6， 4， 4， 6 and 6 strains were equal to or lower than 1， respectively. In time-antibacterial curve， compared with antibiotics alone， the number of colonies decreased by 2.65， 2.30， 0.42， 0.47， 0.53， 1.19， 1.74， 1.04 lgCFU/mL respectively after ampelopsin combined with ceftriaxone， cefperazone/sulbactam， piperacillin/tazobactam， cefoperazone， ciprofloxacin， amikacin， piperacillin and cefepime. CONCLUSIONS： Ampelopsin combined with ceftriaxone and cefoperazone/sulbactam show better antibacterial effect on PA.